Is lurbinectedin safe for infants?
No clinical data or studies evaluate lurbinectedin use in infants. The drug, approved as Zepzelca for small cell lung cancer in adults, carries explicit warnings against use in pregnant or breastfeeding individuals due to embryo-fetal toxicity risks observed in animal studies. No human infant exposure data exists, and pediatric approval is absent.[1][2]
Pregnancy and reproductive risks
Lurbinectedin caused post-implantation loss, decreased fetal weight, and skeletal/organ malformations in rats and rabbits at doses below human equivalents. It is pregnancy category not assigned (high risk), with recommendations for contraception and pregnancy testing before starting treatment.[1][2]
Breastfeeding and lactation exposure
Avoid breastfeeding during treatment and for at least 14 days after the last dose. Lurbinectedin or its metabolites pass into milk in animal models, posing unknown risks to nursing infants.[1]
Why no infant data?
Infant pharmacokinetics, dosing, or safety have not been studied. Labeling restricts use to adults (18+), with no pediatric indications. Off-label use in infants lacks evidence and could lead to severe toxicity given the drug's DNA-binding mechanism.[1][2]
Related patient concerns
Patients ask about fertility effects (may impair male/female fertility reversibly) and long-term offspring risks, but infant-specific side effects remain unstudied. Consult oncology specialists for alternatives in rare pediatric cases.[1]
[1]: Zepzelca (lurbinectedin) prescribing information, Jazz Pharmaceuticals, https://www.zepzelca.com/pdf/Zepzelca-PI.pdf
[2]: FDA label for Zepzelca, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213069s000lbl.pdf